NEW YORK--(Business Wire)--
Enzo Biochem, Inc. (NYSE:ENZ), a leading vertically integrated clinical lab,
life sciences and therapeutic biotechnology company, announced today that Barry
Weiner, President, and David Goldberg, Vice President, Corporate Development,
will be presenting at the Lazard Capital Markets 6th Annual Healthcare
Conference on Tuesday, November 17, 2009 at 3:40 PM at The St. Regis Hotel in
New York, N.Y.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and licensing
of innovative health care products and technologies based on molecular biology
and genetic engineering techniques, and in providing diagnostic services to the
medical community. Enzo`s Life Sciences division develops, produces and markets
proprietary labeling and detection products for gene sequencing, genetic
analysis and immunological research among others. Its catalog of over 40,000
products serves the molecular biology, drug discovery and pathology research
markets. The Company's therapeutic division is in various stages of clinical
evaluation of its proprietary immune regulation medicines for uveitis and
Crohn's disease and conducts pre-clinical research on several candidate
compounds aimed at producing new mineral and organic bone, including technology
that could provide therapy for osteoporosis and fractures, among other
applications. Enzo`s Clinical Labs division provides routine and esoteric
reference laboratory services for physicians in the New York Metropolitan and
New Jersey areas. Underpinning the Company`s technology and operations is an
extensive intellectual property estate in which Enzo owns or licenses over 230
patents worldwide, and has pending applications for over 200 more. For more
information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release
may be considered "forward-looking" statements within the meaning of Section 27A
of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Such statements include declarations regarding
the intent, belief or current expectations of the Company and its management.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and uncertainties
that could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of developments
occurring after the date of this press release.
For: Enzo Biochem, Inc.
Steven Anreder, 212-532-3232
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
Copyright Business Wire 2009
